Orient Pharma (Samoa) Co., Ltd
Records under this name other than patents Orient Pharma (Samoa) Co., Ltd holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 2 of 2 · Back to Orient Pharma (Samoa) Co., Ltd
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,658,683 | Combination of alpha-2 receptor agonist (clonidin) and anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea Lapsed on the fee record Ended Feb 25, 2026 · USPTO record | Lapsed on the fee record | Ended Feb 25, 2026 | USPTO record |
| US 8,481,583 | Combination of alpha-2 receptor agonist (clonidin) and anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea Lapsed on the fee record Ended Jul 9, 2025 · USPTO record | Lapsed on the fee record | Ended Jul 9, 2025 | USPTO record |